Brolucizumab–dbll: Revision history

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

14 March 2025

  • curprev 10:3510:35, 14 March 2025 Omid Afkhami-Ardakani talk contribs 6,665 bytes +6,665 Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Brolucizumab-dbll |aOrAn=a |drugClass=Vascular Endothelial Growth Factor (VEGF) Inhibitor |indicationType=treatment |indication=Neovascular (Wet) Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME) |adverseReactions=Vision blurred, Cataract, Conjunctival hemorrhage, Eye pain, and Vitreous floaters. |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWa..."
Retrieved from "https://www.wikidoc.org/index.php/Brolucizumab–dbll"